| Chine | Turquie | Espagne | |
| Traitement de la maladie d'Alzheimer à l'aide de cellules souches | de $22,000 | de $15,000 | de $20,000 |
Bookimed ne rajoute pas de frais pour les traitements de La maladie d'Alzheimer. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de La maladie d'Alzheimer et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de La maladie d'Alzheimer.
Professor ZHENG Wei Hong is Director of the Department of Neurology and the discipline leader. He previously served as Director of Neurology at Xiamen University Affiliated Zhongshan Hospital. He is a Professor at Xiamen University and a master's supervisor.
His clinical focus includes etiological investigation, prevention, and treatment of cerebral infarction and cerebral hemorrhage. He also diagnoses and treats complex neurological diseases, including epilepsy, neuroimmunological and neuromuscular disorders (myasthenia gravis, multiple sclerosis), and Parkinson's disease.
Appointments: He serves as a committee member of the Neuroimmunology Group (Chinese Medical Association Neurology Branch), the Immunology Branch (Chinese Stroke Association), Neurorestoration (Chinese Medical Doctor Association), and Cognitive Impairment (Chinese Geriatrics Society). He is on the Standing Committee of the Expert Committee of Stroke Screening and Prevention Engineering Base Hospitals (Ministry of Health). He is a member of the Neurology Expert Group, Fujian Provincial Medical Quality Control Center for Stroke and Epilepsy. He is Standing Director of the Fujian Anti‑Epilepsy Association. He is Deputy Group Leader of the Epilepsy and Electroencephalography Group (Fujian Medical Association Neurology Branch). He is Deputy Chairperson of the 1st Committee, Neurology Physicians Branch (Fujian Medical Doctor Association). He is a Standing Committee Member (5th–7th) of the Neurology Branch (Fujian Medical Association). He is Deputy Chairperson of the Neurology Professional Committee (Xiamen Medical Association).
Neurologue de premier plan et docteur en sciences médicales, ayant suivi une formation postdoctorale à l'université de Harvard et dans d'autres institutions prestigieuses.
Alzheimer’s disease treatment in China is safe when patients choose accredited tertiary facilities like Dr. Eber Brain Hospital. These centers employ specialists with training from Harvard and UT. Standard protocols include globally approved monoclonal antibodies. Patients must prioritize JCI or ISO-certified hospitals to ensure Western-level safety standards.
Bookimed Expert Insight: While many seek low-cost options, safety in China is tied to academic credentials rather than price. Our data shows that top-performing neurologists, such as Dr. Zheng Wei Hong, often hold dual roles as university professors and committee members for the Ministry of Health. Selecting a doctor with these institutional ties ensures the treatment follows national safety guidelines and uses verified pharmaceutical chains.
Patient Consensus: Patients emphasize the need for independent medical translators to bridge language gaps in public hospitals. They also recommend verifying clinical trial data before traveling for any experimental stem cell procedures.
Alzheimer treatment in China includes anti-amyloid monoclonal antibodies like Lecanemab and unique domestic medications such as Sodium Oligomannate. Specialized centers provide stem cell therapy and neurostimulation. These modalities target amyloid plaques, gut microbiome regulation, and cognitive rehabilitation within modern tertiary-level facilities.
Bookimed Expert Insight: Leading neurologists like Dr. Shao Ming at Dr. Eber Brain Hospital often bring prestigious international training from Harvard and the University of Texas to Chinese treatment protocols. This background allows them to combine domestic drug innovations with Western diagnostic precision in complex neurology cases. Patients should look for doctors with such global credentials when seeking advanced neurophysiological monitoring.
Patient Consensus: Patients note that standard drugs are easily accessible in major cities, but emphasize that integrated TCM approaches like acupuncture often work best when combined with Western medicine. Families suggest focusing on Tier-1 city hospitals to ensure access to authentic medications and avoid counterfeit risks.
Eligibility for Alzheimer’s therapy depends on a clinical diagnosis of mild cognitive impairment or early-stage dementia. Patients must prove amyloid-positive status via PET scans or cerebrospinal fluid analysis. While guidelines focus on adults aged 50 to 90, cognitive stage and overall health outweigh biological age.
Bookimed Expert Insight: Focus on tertiary centers in tier-1 cities like Beijing or Tianjin for complex diagnostics. Dr. Eber Brain Hospital in Tianjin features 63 departments specializing in neurological restoration. Specialized neurologists like Dr. Shao Ming at this facility have extensive international research experience in memory impairment. This high level of specialization is critical because general hospitals may delay the biomarkers testing required for early treatment.
Patient Consensus: Patients emphasize that the diagnosis process often takes over a year. Many regret waiting and advise seeking a neurologist immediately rather than relying on primary care visits. They note that being proactive with amyloid testing is the only way to catch the narrow window for newer therapies.
Patients should anticipate gastrointestinal distress or neurological changes from Alzheimer’s medications in China. Newer amyloid-targeting antibodies like lecanemab carry a 9.4% risk of microhemorrhages. Symptom-relieving drugs often cause nausea or insomnia. Specialized monitoring helps manage these risks safely within Chinese clinical settings.
Bookimed Expert Insight: Coordination of care is vital when combining Western drugs with Traditional Chinese Medicine (TCM). Our data shows that top neurologists like Dr. Zheng Wei Hong at Xiamen Humanity Hospital specialize in both cognitive impairment and neuroimmunology. This dual expertise is crucial because internal research suggests herbal combinations can sometimes lead to unpredictable bleeding risks or increased sedation when used alongside standard prescriptions. We recommend patients verify all medications through hospital pharmacies to ensure authenticity and safety.
Patient Consensus: Many families report being surprised by heart rate drops or fainting. They emphasize the need to start with low doses and verify all medications at hospital pharmacies to avoid quality issues.
International patients typically stay in China for 1 to 4 weeks for initial Alzheimer’s evaluation and therapy. This period covers specialized biomarker testing and neuroimaging. It also includes the start of protocols like stem cell therapy or specific localized drug monitoring. Professional medical support is essential for communication.
Bookimed Expert Insight: While small clinics may offer 10-day diagnostic windows, quaternary centers like Dr. Eber Brain Hospital operate with over 400 doctors across 63 departments. This massive scale often means internal coordination takes longer but provides more thorough results. A 4-week stay is actually safer for patients traveling long distances to manage any initial treatment side effects.
Patient Consensus: Patients emphasize budgeting 6 weeks to avoid rushed protocols and account for potential language barriers. Many suggest securing travel insurance that covers experimental treatments to handle unexpected extensions or observation needs.
Continuing Alzheimer medication from China depends on local drug approval and customs rules. Globally approved drugs like Lecanemab are often transferable. However, China-specific treatments like Oligomannate or stem cell therapy protocols require a local neurologist assessment for long-term care in your home country.
Bookimed Expert Insight: While China leads in neurorestorative research at facilities like Dr. Eber Brain Hospital, these advanced protocols often differ from Western standards. Our data shows that doctors like Dr. Zheng Wei Hong emphasize a transition period where home doctors perform fresh bloodwork before re-prescribing. Do not assume your home neurologist will continue a Chinese protocol without first reviewing these specific clinical records.
Patient Consensus: Patients note that keeping medications in original containers with English labels is vital for passing customs. Many recommend coordinating with a local neurologist before leaving China to avoid gaps in daily treatment.
Clinical follow-up for Alzheimer's treatment in China typically involves virtual monitoring rather than mandatory in-person tests. Patients should prioritize rest and hydration before traveling home. Standard medical evaluations by a local neurologist are recommended within 1 to 3 months to track cognitive progress objectively.
Bookimed Expert Insight: Chinese neurology centers like Dr. Eber Brain Hospital emphasize multidisciplinary approaches including rehabilitation. Because international data coordination is limited, patients should record their own baseline metrics before treatment. This creates a clear benchmark for local doctors to measure post-treatment improvements in motor function or memory.
Patient Consensus: Patients note that formal follow-up is often just a brief video call or phone quiz. Many recommend using independent cognitive apps and private scans at home to verify any neural changes described by the clinic.